Skip to main content

Table 1 Patient characteristics in different groups

From: The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome

Parameter

All: n (%), median [min, max]

Group 1: n (%), median [min, max]

Group 2: n (%), median [min, max]

Group 3: n (%), median [min, max]

Age, years

62 [23, 90]

58 [23, 75]

62 [27, 84]

68 [48, 90]

Male/female

33/22

9/8

15/9

9/5

BMI, kg/m2

24.8 [15.2, 94.5]

24.0 [16.8, 94.5]

25.0 [20.4, 49.2]

26.0 [19.0, 30.1]

CRP d1 (mg/dL)

12.0 [0.7, 36.4]

9.8 [0.7, 32.5]

13.8 [1.1 28.2]

12.7 [0.7, 36.4]

ΔCRP (d1–d3, mg/dL)

3.0 [− 17.1, 18.2]

− 0.3 [− 17.1, 17.9]

4.5 [− 11.5, 12.8]

4.45 [− 6.0, 18.2]

IL-6 d1 (pg/mL)

93.1 [4, 2469]

101 [50.6, 470]

90.2 [5.1, 530]

108.2 [10.7, 2469]

ΔIL-6 (d1–d3, pg/dL)

48 [− 727, 2327]

50 [− 727, 433]

46.5 [− 138, 486]

84.7 [− 68.1, 2327]

APACHE II d1

25 [12, 51]

24 [16, 34]

25 [12, 37]

28.5 [18, 51]

ΔAPACHE–II (d1–d3)

4 [− 13, 22]

8 [− 6, 17]

3 [− 7, 22]

4 [− 13, 14]

SOFA d1

10 [3, 19]

9 [3, 14]

11 [5, 16]

11 [3, 19]

ΔSOFA (d1–d3)

4 [− 8, 9]

2 [− 8, 9]

2 [− 2, 7]

2 [− 4, 6]

Body temperature > 38.0 °C d1

17 (30.1)

4 (23.5)

9 (37.5)

4 (28.6)

Catecholamine therapy d1

45 (81.8)

12 (70.6)

20 (83.3)

13 (92.9)

Invasive ventilation d1

41 (74.5)

11 (64.7)

18 (75.0)

12 (85.7)

Bilirubin d1 (mg/dL)

0.9 [0.2, 11.9]

0.8 [0.2, 10]

0.9 [0.2, 4.9]

0.9 [0.4, 11.9]

ΔBilirubin (d1–d5, mg/dL)

0.2 [− 6.1, 8.7]

0.2 [− 1.5, 1.1]

0.2 [− 0.3, 2.3]

0.1 [− 6.1, 8.7]

AST d1 (U/L)

69.5 [16, 1359]

92 [52, 850]

64 [16, 1359]

61 [25, 693]

ΔAST (d1–d5, U/L)

25 [− 563, 1223]

47 [− 60, 792]

8 [− 563, 1223]

0 [− 168, 645]

ALT d1 (U/L)

29 [7, 2018]

28 [14, 987]

30 [8, 2018]

23 [7, 695]

ΔALT (d1–d5, U/L)

− 3 [− 322, 1662]

− 3 [− 40, 741]

− 5 [− 322, 1662]

1 [− 250, 415]

GGT d1 (U/L)

38 [11, 850]

28 [14, 547]

41 [11, 850]

97.5 [11, 618]

ΔGGT (d1–d5, U/L)

− 30 [− 1643, 457]

− 30 [− 522, 249]

− 29.5 [− 603, 101]

− 30.5 [− 1643, 457]

Creatinine d1 (mg/dL)

0.8 [0.4, 5.3]

0.7 [0.5, 1.2]

0.8 [0.6, 1.8]

1.2 [0.8, 5.3]

Δ creatinine (d1–d5, mg/dL)

0.05 [–3.4, 2]

0.0 [− 0.3, 2]

0.1 [–0.5, 0.7]

0.0 [–3.4, 0.4]

Urea d1 (mg/dL)

34 [18,131]

30.5 [18, 61]

34 [20, 131]

71 [29, 113]

Δ urea (d1–d5, mg/dL)

− 9.5 [− 134, 51]

− 9.5 [− 48, 9]

− 7 [− 134, 51]

− 23 [− 76, 27]

CLCR d1 (mL/min)

79 [4, 200]

146.5 [59, 200]

76 [13, 170]

42 [4, 80]

Δ CLCR (d1–d5, mL/min)

− 17 [− 139, 78]

5.5 [− 139, 78]

− 24.5 [− 116, 70]

− 10 [− 41, 3]

RRT

9 (16.4)

1 (5.9)

3 (12.5)

5 (35.7)

ECMO d1

2 (3.6)

0 (0.0)

1 (4.2)

1 (7.1)

In-hospital mortality

13 (23.6)

3 (17.6)

2 (8.3)

8 (57.1)

Trough-level meropenem (mg/L)

5.0 [0.25, 65.3]

1.85 [0.25, 20.4]

5.4 [2.17, 27.4]

18.3 [8.48, 65.3]

Trough-level piperacillin (mg/L)

40.1 [0.5, 400]

8.09 [0.5, 27.2]

25 [7.2, 156]

89.2 [46, 400]

  1. CRP C-reactive protein, d1 day 1 of evaluation, IL-6 interleukin-6, AST serum aspartate aminotransferase, ALT serum alanine aminotransferase, GGT glutamine-glutamyl transferase, CLCR creatinine-clearance, RRT renal replacement therapy, ECMO extracorporeal membrane oxygenation, d1–d5 day 1–day 5
Back to article page

Journal of Intensive Care

ISSN: 2052-0492